Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636283 · ClinicalTrials.gov registry record · Phase 2
Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
A Phase 2 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02636283 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 6 participants.
The verdict
NCT02636283, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
Interventions
- DRUG Entresto
- DRUG Placebo group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-31 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02636283
The ClinicalTrials.gov registry entry for NCT02636283 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entresto is the first listed.
NCT02636283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02636283 about?
NCT02636283 is a clinical study titled "Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease". This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
What is the current status of trial NCT02636283?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-12-31. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT02636283?
The interventions under investigation include: Entresto (DRUG), Placebo group (DRUG).
Who is sponsoring clinical trial NCT02636283?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.